HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RMD
ResMed Inc.
RMD's fundamentals are strong and it looks cheap: trading at 22x earnings, below its usual 37x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
RMD's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $239 | — |
| Current | 22x | $239 | — |
| Cheap | 26x | $280 | +17% |
| Fair | 37x | $410 | +71% |
| Expensive | 54x | $595 | +149% |
Historical ranges are pointers, not guarantees.
RMD's PE is in its cheap range at 22x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RMD Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect RMD's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $12.30 | +12% |
| Q3 2026 | $10.98 | +12% |
| Q2 2026 | $10.43 | +9.7% |
| Q1 2026 | $10.37 | +17% |
| Q4 2025 | $10.11 | +20% |
| Q3 2025 | $9.77 | +30% |
| Q2 2025 | $9.51 | +37% |
| Q1 2025 | $8.90 | +37% |
| Q4 2024 | $8.46 | +40% |
RMD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RMD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
RMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +5.9% |
| Q2 2026 | $1.5B | +8.6% |
| Q1 2026 | $1.4B | +11% |
| Q4 2025 | $1.4B | +11% |
| Q3 2025 | $1.3B | +9.1% |
| Q2 2025 | $1.3B | +10% |
| Q1 2025 | $1.3B | +7.9% |
| Q4 2024 | $1.3B | +10% |
RMD's revenue has grown year over year for 22 quarters in a row: $1.4B last quarter, up 5.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.4 points |
| Q2 2026 | 31% | -3.1 points |
| Q1 2026 | 35% | +1.9 points |
| Q4 2025 | 35% | +2 points |
| Q3 2025 | 33% | +1.8 points |
| Q2 2025 | 34% | +2.5 points |
| Q1 2025 | 33% | +1.7 points |
| Q4 2024 | 33% | +8.9 points |
RMD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RMD on cash flow, with more consistent year-over-year improvement.
RMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $373.7M | -9.8% |
| Q2 2026 | $403.5M | -21% |
| Q1 2026 | $520.5M | -6.7% |
| Q4 2025 | $311.2M | +8.1% |
| Q3 2025 | $414.4M | +35% |
| Q2 2025 | $508.2M | +22% |
| Q1 2025 | $557.9M | +46% |
| Q4 2024 | $288M | +15% |
RMD generated $1.6B in free cash flow over the past year, down 9% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.8% | -2.6M shares |
| 1 year | -2.4% | -3.5M shares |
| 3 years | -2.8% | -4.1M shares |
| 5 years | -2.3% | -3.4M shares |
| Available history | -1.5% | -2.2M shares |
RMD has 143M diluted shares, down 2.4% from a year ago, with $1.5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $936.4M |
| Q2 2026 | $200M |
| Q1 2026 | $175M |
| Q4 2025 | $175M |
| Q3 2025 | $150M |
| Q2 2025 | $100M |
| Q1 2025 | $75M |
| Q4 2024 | $75M |
RMD spent $1.5B buying back its own shares over the past year, about four times what it spent the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.5x | Net Cash |
| Q4 2025 | -0.4x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | 0.1x | Very low |
RMD has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.7 | Neutral |
| Stochastic | 60.7 | Neutral |
RMD's weekly RSI is 56 (neutral) and its Stochastic is 61 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RMD PE vs Healthcare Sector
| Metric | RMD | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 26x | 16% below |
| PE % | 6 | 29 | 23 pts below |
RMD is trading at 22x earnings, a 16% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $233.4 | 2.4% above |
| 20 week MA | $223.3 | 7% above |
| 50 week MA | $227.8 | 4.8% above |
| 100 week MA | $238.7 | 0.1% above |
| 200 week MA | $220.5 | 8.3% above |
RMD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
RMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $156.2 | $212.4 | +36% |
| 2021 | $212.4 | $258.8 | +22% |
| 2022 | $258.8 | $208.3 | -20% |
| 2023 | $208.3 | $172.0 | -17% |
| 2024 | $172.0 | $233.2 | +36% |
| 2025 | $233.2 | $244.8 | +5% |
| 2026 YTD | $244.8 | $238.9 | -2.4% |
RMD has the edge over HIMS on returns for 2026, with the stronger performance.